Encore Medical, which makes transcatheter implants to repair cardiac defects, filed on Monday with the SEC to raise up to $17 million in an initial public offering.
The company develops and manufactures septal occlusion devices, which are implantable products delivered via catheter to repair certain cardiac defects, such as patent foramen ovale (PFO). Encore’s devices are approved for sale in the European Union, and while it does not have regulatory approval to sell its devices in the US, the company has received approval from the FDA to conduct trials to obtain market clearance.
The Eagan, MN-based company was founded in 2017 and booked $2 million in revenue for the 12 months ended June 30, 2025. It plans to list on the NYSE American under the symbol EMI. Oak Ridge Financial and Dawson James are the joint bookrunners on the deal. No pricing terms were disclosed.
